HC Wainwright & Co. Reiterates Buy on IO Biotech, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated a Buy rating for IO Biotech, maintaining a price target of $12.
September 03, 2024 | 10:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for IO Biotech, maintaining a price target of $12, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $12 price target by HC Wainwright & Co. suggests a positive outlook for IO Biotech, likely boosting investor confidence and potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100